Navigation Links
Cutting Off Blood Flow Limits Damage During Heart Attack
Date:2/26/2010

Repeatedly inflating blood pressure cuff led to 30 percent reduction in lost cardiac tissue, study found

FRIDAY, Feb. 26 (HealthDay News) -- Cutting off the flow of blood to the arm by repeatedly inflating a blood pressure cuff appears to reduce the amount of tissue damaged during a heart attack, a new Danish study shows.

This procedure somehow has a protective effect on heart muscle, by mechanisms that are not yet understood, the researchers said.

In a study of 142 patients being rushed to a hospital for treatment of severe heart attacks, the amount of heart tissue saved for those who got the treatment, called induced ischemia, was 30 percent greater than for those who didn't, according to a report in the Feb. 27 issue of The Lancet.

"For patients being transported to the hospital for acute myocardial infarction [heart attack], we inflated the blood pressure cuff for five minutes, relaxed it and repeated it four times," said study author Dr. Hans Erik Botker, a professor of cardiology at Aarhus University Hospital in Skejby.

While the initial results appear promising, induced ischemia is not being used routinely, Botker said. "We have demonstrated cardioprotection by decrease of the infarct [damaged heart muscle]," he explained. "But this is a surrogate marker. The question is whether it translates into clinical benefit for the patient. We have shown improvement during hospitalization, but it was not sustained for more than 30 days. Now, we need to follow more patients for longer times to clarify whether there is clinical benefit."

The induced ischemia trial is the latest in a long series of studies, first in animals and now in humans, which started with the observation that brief stoppages of blood flow can improve the ability of an organ to withstand stress, Botker said. He and his colleagues have been working with the technique since 2002, with animal experiments followed by trials in people undergoing bypass surgery and now the heart attack trial.

More studies are needed to determine whether the procedure reduces the incidence of congestive heart failure and death, Botker said. "To be honest, we need these clinical endpoints," he said. "To show that the therapy translates into clinical benefit, that is the next step."

Most of the work on induced ischemia is being done in Europe. In the United States, a group led by Jacob Vinten-Johansen, a professor of cardiothoracic surgery at Emory University in Atlanta, has been trying a variation on the theme, in which blood flow is interrupted by inflating the balloon on a catheter, the thin wire inserted for the artery-opening procedure called angioplasty.

"We were the first to try it, in 2003," Vinten-Johansen said. "We did a series of pilot studies simulating models of myocardial infarction. We did find it beneficial and went through the litany of what would be rational and effective. Essentially, in a nutshell, a little bit of ischemia can be helpful and a little bit of reperfusion can be helpful."

The beauty of the technique is its simplicity, Vinten-Johansen said, but there are complexities within the simplicity. While one small human trial is under way at Emory, "we still are looking at preclinical work, what makes it tick, what are the mechanisms," he said. "We want to answer some questions about why this thing is doing what it is doing."

So far, there have been only small human trials of induced ischemia, generally in single medical centers in Europe, Vinten-Johansen said. "The U.S. cardiology community is a bit slower to embrace these things, and the regulatory situation is better in Europe," he explained.

U.S. regulations require signing of a consent form for such an experimental procedure, "and that is difficult when the patient is in an ambulance coming into the hospital," said Dr. Ajay J. Kirtane, an interventional cardiologist at New York-Presbyterian Hospital/Columbia Medical Center.

Caution about the technique is advisable because "particularly for patients with acute heart attacks, many interventions have shown promise in single-center trials but have not had the same effect in multi-center trials," Kirtane said.

But induced ischemia does have appeal, he said. "If you can consistently have the same kind of outcome these doctors have observed, that is pretty exciting," Kirtane said.

A report in the Feb. 26 online edition of The Lancet described a study led by British researchers that found that surgery to remove blockages in the carotid artery, the main blood vessel to the brain, is safer and better at preventing a stroke than implanting a stent, a thin metal tube, to improve blood flow.

More information

Current heart attack treatments are described by the American Heart Association.



SOURCES: Hans Erik Botker, M.D., professor, cardiology, Aarhus University Hospital, Skejby, Denmark; Jacob Vinten-Johansen, Ph.D, professor, cardiothoracic surgery, Emory University, Atlanta; Ajay J. Kirtane, M.D., interventional cardiologist, New York-Presbyterian Hospital/Columbia Medical Center, New York City; Feb. 27, 2010, The Lancet


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Over 500,000 Health Care Providers Now Cutting Costs, Saving Time Through CAQH Administrative Simplification Initiative
2. Cutting Salt Wont Affect Foods Safety
3. Prize for Cutting-Edge Laser Innovations
4. Fern Tree, The Spa at Half Moon, Jamaicas Premier Spa, Opens With Ceremonial Ribbon Cutting
5. The era of global aging: GSA showcases cutting-edge San Francisco meeting topics
6. Cutting Edge CyberKnife Cancer Treatment Center to Open in Tampa Bay Area
7. Financial incentives may hold key to cutting child malaria deaths
8. FDA Mulls Cutting Salt in Processed Foods
9. New Democracy Corps Battleground Poll of Swing Districts Finds Strong, Bi-Partisan Opposition to Cutting Medicare-Funded Nursing Home Care
10. Cutting caffeine may help control diabetes
11. Verizon teams with MCG to test cutting-edge technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... 2017 , ... A Palm Beach doctor plans to run the 2017 London ... provides free surgery to poor children suffering from cleft lip and cleft palate. , ... to support the efforts of the American Heart Association and the Leukemia and Lymphoma ...
(Date:1/18/2017)... ... January 18, 2017 , ... Dr. Farhan Qureshi is an ... implants dentistry. His modern dental practice has two convenient office locations in Alexandria and ... Rated Dentist for the Alexandria area. This award confirms the fact that ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... gum disease to enamel erosion, and those dental problems can increase the risk ... Health, many pregnant women are failing to get the dental care they need. ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... of difference. Eden Activewear is a stand-out company for several differences from other ... and only manufacture on demand, this is called 'Agile' manufacturing - http://www.leanproduction.com/agile-manufacturing.html ...
(Date:1/17/2017)... St. Petersburg, Florida (PRWEB) , ... January 17, 2017 , ... ... and the Producers of AsSeenOnTV.pro will be featuring DRTV campaigns regarding the topic of ... year to become a better version of themselves. What better way to commit to ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... Jan. 17, 2017 Paragon Bioservices received a ... development services for a variety of National ... medical product development activities. The IDIQ mechanism will ... for task order awards up to $159 million. ... manufacturing and process development of biopharmaceuticals, is one ...
(Date:1/17/2017)... Management to Discuss Acquisition of Oncology ... On Track For An NDA Submission to ...   ... KTOV ; TASE: KTOV), an innovative biopharmaceutical company, announced that it will ... Eastern Time to discuss the recent acquisition of a majority stake in TyrNovo, ...
(Date:1/17/2017)... DUBLIN , Jan. 17, 2017  Jazz Pharmaceuticals ... first patient has been enrolled in a Phase 3 ... versus best supportive care (BSC) in the prevention of ... undergoing hematopoietic stem cell transplant (HSCT) who are at ... VOD.  The defibrotide clinical trial will be conducted across ...
Breaking Medicine Technology: